Abstract
Intrahepatic cholestasis of pregnancy (ICP) is a clinical syndrome of unknown pathophysiology, occurring during the second half of pregnancy and persisting until delivery. The incidence of ICP varies from 0.1% to 1.5% of pregnancies in Europe, North America and Australia and from 9.2% to 15.6% in South American countries such as Bolivia and Chile. This syndrome has been associated with increased foetal distress, intrauterine death, premature delivery, perinatal mortality and, more recently, with the occurrence of respiratory distress syndrome in the newborn infant. Bile acids (BA) are supposed to be the main mediators for these complications because ICP seriously impairs the placental clearance of foetal BA leading to a dangerous accumulation of these compounds within the foetus and the newborn. Cholestatic pregnancies have to be considered high risk ones, recent reports showing that BA can interfere with surfactant metabolism and are particularly harmful for the developing lung. This review summarizes existing literature data on this topic with particular emphasis on bile acids-induced lung injury. The authors discuss possible mechanisms of lung damage and highlight future research perspectives in this field.
Keywords: Lung injury, neonate, bile acids, pneumonia, obstetric cholestasis
Current Pediatric Reviews
Title: Intrahepatic Cholestasis of Pregnancy and Bile Acids Induced Lung Injury in Newborn Infants
Volume: 3 Issue: 2
Author(s): Enrico Zecca, Daniele De Luca, Marco Marras, Giada Barbato and Costantino Romagnoli
Affiliation:
Keywords: Lung injury, neonate, bile acids, pneumonia, obstetric cholestasis
Abstract: Intrahepatic cholestasis of pregnancy (ICP) is a clinical syndrome of unknown pathophysiology, occurring during the second half of pregnancy and persisting until delivery. The incidence of ICP varies from 0.1% to 1.5% of pregnancies in Europe, North America and Australia and from 9.2% to 15.6% in South American countries such as Bolivia and Chile. This syndrome has been associated with increased foetal distress, intrauterine death, premature delivery, perinatal mortality and, more recently, with the occurrence of respiratory distress syndrome in the newborn infant. Bile acids (BA) are supposed to be the main mediators for these complications because ICP seriously impairs the placental clearance of foetal BA leading to a dangerous accumulation of these compounds within the foetus and the newborn. Cholestatic pregnancies have to be considered high risk ones, recent reports showing that BA can interfere with surfactant metabolism and are particularly harmful for the developing lung. This review summarizes existing literature data on this topic with particular emphasis on bile acids-induced lung injury. The authors discuss possible mechanisms of lung damage and highlight future research perspectives in this field.
Export Options
About this article
Cite this article as:
Zecca Enrico, De Luca Daniele, Marras Marco, Barbato Giada and Romagnoli Costantino, Intrahepatic Cholestasis of Pregnancy and Bile Acids Induced Lung Injury in Newborn Infants, Current Pediatric Reviews 2007; 3 (2) . https://dx.doi.org/10.2174/157339607780598994
DOI https://dx.doi.org/10.2174/157339607780598994 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Liposomes as Versatile Platform for Cancer Theranostics: Therapy, Bio-imaging, and Toxicological Aspects
Current Pharmaceutical Design Pain Perception and Management: Where do We Stand?
Current Molecular Pharmacology Recent Clinical Trials in Non-Small Cell Lung Cancer
Current Cancer Therapy Reviews The Structure and Function of Histone Deacetylases: The Target for Anti-cancer Therapy
Current Medicinal Chemistry Diallyl Disulfide Inhibits Breast Cancer Stem Cell Progression and Glucose Metabolism by Targeting CD44/PKM2/AMPK Signaling
Current Cancer Drug Targets EGF Receptor as a Drug Target in Arterial Hypertension
Mini-Reviews in Medicinal Chemistry Current Update on Eosinophilic Lung Diseases and Anti-IL-5 Treatment
Recent Patents on Anti-Infective Drug Discovery The Caveolin-1 Connection to Cell Death and Survival
Current Molecular Medicine Cetuximab Inhibits Gastric Cancer Growth in vivo, Independent of KRAS Status
Current Cancer Drug Targets Prognostic Markers in Small Cell Lung Cancer
Current Cancer Therapy Reviews Review on Documented Medicinal Plants used for the Treatment of Cancer
Current Traditional Medicine The Use of Herbal Medicine in Cancer-related Anorexia/ Cachexia Treatment Around the World
Current Pharmaceutical Design Exosomal miR-214-5p Released from Glioblastoma Cells Modulates Inflammatory Response of Microglia after Lipopolysaccharide Stimulation through Targeting CXCR5
CNS & Neurological Disorders - Drug Targets Imaging of Tumor Angiogenesis: Current Approaches and Future Prospects
Current Pharmaceutical Design Germacrone: A Potent Secondary Metabolite with Therapeutic Potential in Metabolic Diseases, Cancer and Viral Infections
Current Drug Metabolism Recombinant Snake Venom Cystatin Inhibits Tumor Angiogenesis in vitro and in vivo Associated with Downregulation of VEGF-A165, Flt-1 and bFGF
Anti-Cancer Agents in Medicinal Chemistry CARING (CAncer Risk and INsulin analoGues): The Association of Diabetes Mellitus and Cancer Risk with Focus on Possible Determinants - A Systematic Review and a Meta-Analysis
Current Drug Safety Expression and Prognostic Significance of the MMP Family Molecules in Bladder Cancer
Combinatorial Chemistry & High Throughput Screening COX-2, Cell Proliferation and PMA in Head-and-Neck Cancer Cells
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Drug Conjugated Nanomedicine as Prodrug Carrier
Nanoscience & Nanotechnology-Asia